Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Pyridoxal Phosphate Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.97 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.97 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.97 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.60 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.97 |
| ▸ | ACP1 | P24666 | 1/20 | 0.97 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | PNPO | Q9NVS9 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.60 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.58 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | YWHAG | P61981 | 1/20 | 0.44 |
| ▸ | YWHAZ | P63104 | 1/20 | 0.44 |
| ▸ | PDXK | O00764 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxal Phosphate Anhydrous SCHEMBL29392551 | 1.00 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL23158 | 0.99 | P2RX2 (1.00) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL29362986 | 0.99 | P2RX2 (1.00) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL20335524 | 0.97 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL20335516 | 0.97 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL4916108 | 0.97 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL2746592 | 0.97 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL28200961 | 0.93 | ESR1 (0.90) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL29424718 | 0.92 | P2RX2 (0.88) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL10534222 | 0.92 | P2RX2 (0.88) | P2RX2ESR1PTGS1ACP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310936-B2 | Pharmaceutical compositions for the treatment of cancer | SELEQ OY (FI) | 2025-05-27 | — | — | US | claimed |
| CN-116615337-B | Method and kit for three-dimensional (3D) printing | 佩里多特打印有限责任公司 | 2025-04-18 | — | — | CN | claimed |
| US-20230416252-A1 | PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-28 | — | — | US | claimed |
| US-20230391000-A1 | THREE-DIMENSIONAL PRINTING | PERIDOT PRINT LLC | 2023-12-07 | — | — | US | claimed |
| CN-117120418-A | Process for the preparation of compound (I) | 百时美施贵宝公司 | 2023-11-24 | — | — | CN | claimed |
| EP-4237224-A1 | THREE-DIMENSIONAL PRINTING | Hewlett-Packard Development Company, L.P. (US) | 2023-09-06 | — | — | EP | claimed |
| CN-110777190-B | Kit for detecting homocysteine and application thereof | 武汉市长立生物技术有限责任公司 | 2023-08-22 | — | — | CN | claimed |
| CN-116615337-A | Three-dimensional printing | 惠普发展公司，有限责任合伙企业 | 2023-08-18 | — | — | CN | claimed |
| EP-4225757-A1 | A PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}-1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B] [1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | Bristol-Myers Squibb Company (US) | 2023-08-16 | — | — | EP | claimed |
| US-20220235313-A1 | MYCOPLASMA MEDIA FORMULATIONS | ELANCO US INC. | 2022-07-28 | — | — | US | claimed |
| EP-2300598-B1 | USE AND METHODS FOR PREVENTING AND/OR TREATING ORAL MALODOUR | BASF SE (DE) | 2016-04-13 | — | — | EP | claimed |
| US-8142800-B1 | Oral high potency clinical anti-craving treatment and method of use | REAL SUBSTANCE SOLUTIONS, INC. | 2012-03-27 | — | — | US | claimed |
| US-8142799-B2 | High potency clinical anti-craving treatment and method of use | REAL SUBSTANCE SOLUTIONS, INC. | 2012-03-27 | — | — | US | claimed |
| US-20050287226-A1 | High potency clinical anti-craving treatment and method of use | REAL SUBSTANCE SOLUTIONS, INC. | 2005-12-29 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416252-A1 | PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | CYP1B1, AZI2, TET1 | ESR1 4748/4885PTGS1 248/4885PDE4A 2739/4885 |
| US-12310936-B2 | Pharmaceutical compositions for the treatment of cancer | RNASE1, SELENOI, GLS2 | ESR1 2847/4885PTGS1 3553/4885PDE4A 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.